Media OutReach
Vinmec Central Park Performs Vietnam’s First SEEG using AutoGuide Robotic Guidance System for a child diagnosed from refractory epilepsy
This marks the first time in Vietnam that robotic guidance has been used in pediatric epilepsy surgery, — a milestone that opens new possibilities for safer, less invasive, and highly precise treatment options for vulnerable patients. The case also highlights Vietnam’s progress in approaching global standards in advanced epilepsy care.
A 5-Year Search for Seizure-Free Sleep
The patient, B.Q.K. (age 9, from Hanoi), began experiencing seizures in 2021. Despite various treatment regimens and adjustments both domestically and abroad, his condition failed to improve – sometimes experiencing dozens of seizures per day.
For nearly five years, his family sought treatment at numerous medical centers in the hope of giving their child a peaceful night’s sleep without seizures.
According to the World Health Organization (WHO), approximately 30% of epilepsy patients are drug-resistant (1), meaning they do not respond to medication. For these patients, surgery resection of the epileptic zone is often the most effective option. However, accurately localizing the epileptogenic zone – especially in children – is extremely challenging when scalp EEG, MRI, or PET scans provide inconclusive findings.
SEEG and AutoGuide: A Technological Duo to Precisely Locate the “Culprit” in the Brain
Following a thorough multidisciplinary evaluation, doctors at Vinmec Central Park decided to use AutoGuide™ robotic navigation system to perform stereo-electroencephalography (SEEG) to accurately identify the epileptic zone. The robotic guidance ensured high accuracy, faster operative time, and reduced trauma to the brain.
After seven days of SEEG monitoring, the epileptogenic zone was localized in the right orbitofrontal cortex and inferior frontal gyrus—areas densely packed with neural pathways and blood vessels. On June 17, 2025, the epileptic zone removal was performed by Dr. Truong Van Tri and his team at Vinmec Central Park, with technical support from Assoc. Prof. Dr. Shunsuke Nakae, an epilepsy specialist from Japan.
The surgery was successful, with no postoperative neurological deficits. After more than one month of recovery, the patient resumed normal activities and play, with only two minor nocturnal seizures recorded – a reduction of over 95% compared to preoperative frequency.
“For the first time, we achieved near-perfect outcome in pediatric epilepsy surgery thanks to AutoGuide™. This is a critical milestone, especially for young patients who are highly vulnerable to major brain surgery,” said Dr. Tri.
Vinmec: Advancing Neurology with Technology and International Integration
This successful case exemplifies Vinmec’s strategy to build centers of medical excellence through the integration of advanced technology, multidisciplinary expertise, and individualized treatment protocols. Vinmec has been ranked as the No.1 private hospital system in Vietnam for expatriates and international visitors, according to independent patient satisfaction surveys.
Vinmec Central Park is currently one of the few healthcare facilities in Vietnam, placing Vietnam among the few countries in Asia to master this technique—narrowing the gap with global neurology leaders.
(1) https://www.who.int/docs/default-source/mental-health/mhgap/epilepsy-and-seizures/epilepsy-q15.pdf
Hashtag: #Vinmec
The issuer is solely responsible for the content of this announcement.
About Vinmec Health System
Vinmec is a nonprofit healthcare system founded by Vingroup, one of Vietnam’s largest private conglomerates. With 9 international hospitals and 4 international clinics nationwide, Vinmec is committed to delivering international-standard healthcare through subspecialized care, personalized treatment, and cutting-edge medical technology.
Vinmec Central Park in Ho Chi Minh City is the flagship hospital in the network and has been widely recognized as the top private hospital in Vietnam for expatriates and international patients, serving tens of thousands annually.
The hospital excels across several specialties:
- Neurosurgery & Epilepsy: SEEG, robotic-guided surgery, brain tumor resection
- Oncology – Orthopedic Surgery – Cardiology – Advanced Obstetrics & Gynecology
- Allergy & Clinical Immunology: Vietnam’s first and only center recognized as a Center of Excellence by the World Allergy Organization (WAO), in close partnership with Cleveland Clinic (USA) to develop precision medicine and chronic disease management programs
- 3D Medical Technology: Pioneer in 3D-printed titanium implants for complex orthopedic oncology reconstructions
Media OutReach
Zuellig Pharma Acquires Cialis® (Tadalafil) from Lilly in three additional markets in Asia
Following the acquisition, Zuellig Pharma will now own the trademarks, marketing authorizations and license manufacturing know-how for Cialis®, a treatment for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), in 11 markets in Asia, with the expansion of its ownership into three additional markets beyond the original eight. Zuellig Pharma will also continue to promote and distribute the brand in these markets.
The expanded ownership of Cialis® will widen accessibility of the drug to a significant population of men in Asia who are affected by ED and BPH. The acquisition also aligns with Zuellig Pharma’s strategic priority of building a strong portfolio of owned prescription healthcare products as an integrated healthcare solutions company.
“Our acquisition of Cialis® in three additional markets builds on the strong foundation we established two years ago and highlights our proven success in scaling trusted brands effectively through our commercial capabilities and deep expertise. As we broaden our footprint, we remain focused on delivering sustainable growth and advancing our purpose of making in-demand healthcare solutions more accessible to communities in Asia,” said John Graham, CEO of Zuellig Pharma.
Hashtag: #ZuelligPharma #EliLillyandCompany #Cialis #MensHealth #Healthcare #Pharmaceuticals
https://www.zuelligpharma.com/
https://www.linkedin.com/company/zuellig-pharma
The issuer is solely responsible for the content of this announcement.
About Zuellig Pharma
Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.
Media OutReach
Ingdan Powers Embodied AI with Humanoid-Style Brain-Cerebellum Chipset to Boost Robotics Ecosystem
2026 is widely regarded as a milestone year for humanoid robotics, in which humanoid robots transition from laboratory prototypes and demonstration performances to large‑scale mass production. At CES in January, NVIDIA announced the commercial launch of its physical‑AI core platform Jetson Thor. Tesla is scheduled to officially release the mass‑production engineering version of its Optimus (V3) humanoid robot by the end of March, with plans to initiate million‑unit‑level production lines by the end of 2026—an inflection point widely regarded as the “Model 3 moment” of the humanoid robotics industry. At the same time, Chinese robotics companies such as AGIBOT, Unitree, and Fourier Intelligence have already deployed products at scale in warehousing and logistics scenarios.
Against this backdrop, the upstream hardware focus of the humanoid robotics industry is increasingly converging on “Brain-Cerebellum” collaboration and low‑latency, multi‑joint real‑time control, which are essential to achieving coordinated, smooth, and human‑like robotic motion. During the CMG Spring Festival Gala, robots from multiple companies demonstrated complex coordinated movements and dexterous hand operations, further highlighting the value of this technical direction.
D‑Robotics, originating from the AIoT and robotics division of Horizon Robotics, focuses on edge‑side embodied intelligence solutions characterized by high computing power, integrated computation and control, and low latency. Leveraging its parent company’s long‑term experience in intelligent driving, D‑Robotics has established a precise position in humanoid robot “Brain-Cerebellum” coordination and real‑time joint control.
In November 2025, D‑Robotics unveiled its flagship robotics computing platform S600, with an official release planned for the end of the first quarter of 2026. The S600 platform features a highly integrated humanoid‑style “Brain-Cerebellum” chipset architecture. Its “Brain” configuration combines an 18‑core A78AE CPU with a proprietary Nash‑architecture BPU, delivering 560 TOPS (INT8) edge computing power and supporting efficient deployment of VLA, VLM, LLM, and locomotion models. Its “Cerebellum” configuration integrates a 6‑core R52+ MCU, providing high‑reliability, real‑time motion control.
By integrating CPU, BPU, and real‑time MCU capabilities into a single SoC, S600 enables a closed‑loop architecture encompassing perception, decision‑making, and real‑time action control. This design addresses a key industry challenge in which many edge AI processors lack embedded real‑time MCUs and rely on external controllers, resulting in excessive latency. The integrated MCU supports high‑frequency, high‑precision PWM signal generation based on FOC algorithms, enabling precise motor control and contributing to stable rhythm and natural gait.
The S600 platform has been adopted by multiple robotics companies such as Fourier Intelligence, Booster Robotics, X Square Robot, and ROBOTERA, supporting applications that require stable multi‑joint coordination and smooth motion performance.
Ingdan, Inc. (00400.HK) is a core supplier in the AI computing power supply chain and an application technology solutions provider covering both AI infrastructure and AI intelligent terminals. The Company represents a broad portfolio of international semiconductor manufacturers, including NVIDIA, Xilinx, Intel, AMD, and SanDisk, as well as numerous domestic chip vendors. It serves hundreds of robotics manufacturers and Tier‑1 customers and has formed a comprehensive embodied intelligence ecosystem.
D‑Robotics is a core product line Ingdan distributes . Building on D‑Robotics’ products and combined with its own technical services—such as multi‑sensor fusion development, real‑time closed‑loop tuning, Quantization‑Aware Training (QAT) support, simulation testing, and modular SOM customization—the Group has supported sophisticated customers including Galbot and ROBOTERA, continuously enriching the robotics industry ecosystem.
Looking ahead, Ingdan will continue to focus on the humanoid robotics sector. Leveraging an IC product matrix centered on NVIDIA Jetson and D‑Robotics platforms, the Company aims to further strengthen its AI intelligent terminal capabilities and continue supporting the iterative development of embodied intelligence products.
For investor and media enquiries
Please email to **@****an.com
Hashtag: #Ingdan #Chips #humanoid #D‑Robotics #NVIDIA #Tech
The issuer is solely responsible for the content of this announcement.
Ingdan, Inc.
Ingdan, Inc. (00400.HK) is a core supplier in the AI computing power supply chain and an application technology solutions provider covering both AI infrastructure and AI intelligent terminals. The Company represents a broad portfolio of international semiconductor manufacturers, including NVIDIA, Xilinx, Intel, AMD, and SanDisk, as well as numerous domestic chip vendors. It serves hundreds of robotics manufacturers and Tier‑1 customers and has formed a comprehensive embodied intelligence ecosystem.
Media OutReach
Snow, Ice, and Performance: 2026 Changan Global Testing Season Arrives in Europe with Back-to-Back Winter Events
- European dealers and journalists experienced the CHANGAN DEEPAL S05 AWD at 2026 Changan Global Testing Season this February.
- With intelligent AWD and advanced ADAS, the CHANGAN DEEPAL S05 AWD offered uncompromising safety and control on winter roads.
Saalfelden, Austria – Media OutReach Newswire – 12 March 2026 – Following extreme cold tests in Yakeshi, China, the 2026 Changan Global Testing Season made its European debut this February with the Changan Winter Experience in Courmayeur and the Winter Test Drives in Saalfelden. The all-electric CHANGAN DEEPAL S05 AWD was tested on snow and ice—familiar conditions for European drivers—offering dealers and journalists an immersive introduction to Changan’s electric mobility vision through dynamic drives.
Three-time Olympic gold medalist and Milano Cortina 2026 Ambassador Deborah Compagnoni joined the event in Courmayeur, testing the CHANGAN DEEPAL S05 AWD. Her career—defined by determination, control, and reliability—reflects Changan’s core values. “I felt that the principles of trajectory and speed in skiing apply to driving. With this model, you gain confidence on challenging terrain,” she said.
Snow-Validated Performance: The CHANGAN DEEPAL S05 AWD
Tested in Europe, the CHANGAN DEEPAL S05 AWD demonstrated controllable dynamics, reliable traction, and enhanced safety—highlighting its cutting-edge AWD and ADAS. The system adapts seamlessly: ECO/COMFORT modes prioritize RWD efficiency, while AWD will engage automatically when sensors detect slip, high torque demand, or extreme cold below -25°C. SPORT mode delivers permanent 50:50 torque for sharper response. SNOW mode maintains balanced torque with optimized slip control for confident driving on low-grip surfaces.
The intelligent AWD system delivers up to 320 kW power, 502 Nm torque, and 0–100 km/h acceleration in 5.5 seconds. It also improves hill climbing with a 40% gradient capability, ensures stability by actively balancing power to prevent skidding, and enables safer cornering at higher speeds through optimized grip and vehicle dynamics.
Changan Standard: Proven in the Alps, Bound for the World
Changan Standard is defined by a principle: forged in extremes, built for every day. From Yakeshi to the Alps, the test environments are selected to verify specific performance attributes—safety technologies, chassis response, all-wheel-drive calibration, and ADAS in low-grip scenarios. The objective of 2026 Global Testing Season is not to demonstrate extremes, but to confirm consistency: that the same level of safety, control, and stability demonstrated will be replicated in Mexico, Thailand, and Saudi Arabia.
Hashtag: #Changan
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn












